These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34849615)

  • 1. Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial.
    Chuah CH; Chow TS; Hor CP; Cheng JT; Ker HB; Lee HG; Lee KS; Nordin N; Ng TK; Zaid M; Zaidan NZ; Abdul Wahab S; Adnan NA; Nordin N; Tee TY; Ong SM; Chidambaram SK; Mustafa M;
    Clin Infect Dis; 2022 Aug; 75(1):e432-e439. PubMed ID: 34849615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.
    Udwadia ZF; Singh P; Barkate H; Patil S; Rangwala S; Pendse A; Kadam J; Wu W; Caracta CF; Tandon M
    Int J Infect Dis; 2021 Feb; 103():62-71. PubMed ID: 33212256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE).
    Smith T; Hoyo-Vadillo C; Adom AA; Favari-Perozzi L; Gastine S; Dehbi HM; Villegas-Lara B; Mateos E; González YSP; Navarro-Gualito MD; Cruz-Carbajal AS; Cortes-Vazquez MA; Bekker-Méndez C; Aguirre-Alvarado C; Aguirre-Gil G; Delgado-Pastelin L; Owen A; Lowe D; Standing J; Escobedo J
    Trials; 2022 Jul; 23(1):583. PubMed ID: 35869526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
    Doi Y; Hibino M; Hase R; Yamamoto M; Kasamatsu Y; Hirose M; Mutoh Y; Homma Y; Terada M; Ogawa T; Kashizaki F; Yokoyama T; Koba H; Kasahara H; Yokota K; Kato H; Yoshida J; Kita T; Kato Y; Kamio T; Kodama N; Uchida Y; Ikeda N; Shinoda M; Nakagawa A; Nakatsumi H; Horiguchi T; Iwata M; Matsuyama A; Banno S; Koseki T; Teramachi M; Miyata M; Tajima S; Maeki T; Nakayama E; Taniguchi S; Lim CK; Saijo M; Imai T; Yoshida H; Kabata D; Shintani A; Yuzawa Y; Kondo M
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care.
    Shah PL; Orton CM; Grinsztejn B; Donaldson GC; Crabtree Ramírez B; Tonkin J; Santos BR; Cardoso SW; Ritchie AI; Conway F; Riberio MPD; Wiseman DJ; Tana A; Vijayakumar B; Caneja C; Leaper C; Mann B; Samson A; Bhavsar PK; Boffito M; Johnson MR; Pozniak A; Pelly M;
    Lancet Respir Med; 2023 May; 11(5):415-424. PubMed ID: 36528039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Findings from a discontinued clinical trial of favipiravir in high-risk patients with early-onset COVID-19.
    Iwata S; Kobayashi O; Kurashima K; Doi Y; Kunishima H; Shinkai M; Tsushima K; Yamato M; Kano A; Hibino M; Yamatake T; Sakurai T; Ogura T
    J Infect Chemother; 2024 Mar; 30(3):219-227. PubMed ID: 37832822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial.
    Lim SCL; Hor CP; Tay KH; Mat Jelani A; Tan WH; Ker HB; Chow TS; Zaid M; Cheah WK; Lim HH; Khalid KE; Cheng JT; Mohd Unit H; An N; Nasruddin AB; Low LL; Khoo SWR; Loh JH; Zaidan NZ; Ab Wahab S; Song LH; Koh HM; King TL; Lai NM; Chidambaram SK; Peariasamy KM;
    JAMA Intern Med; 2022 Apr; 182(4):426-435. PubMed ID: 35179551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.
    Khamis F; Al Naabi H; Al Lawati A; Ambusaidi Z; Al Sharji M; Al Barwani U; Pandak N; Al Balushi Z; Al Bahrani M; Al Salmi I; Al-Zakwani I
    Int J Infect Dis; 2021 Jan; 102():538-543. PubMed ID: 33181328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.
    Luvira V; Schilling WHK; Jittamala P; Watson JA; Boyd S; Siripoon T; Ngamprasertchai T; Almeida PJ; Ekkapongpisit M; Cruz C; Callery JJ; Singh S; Tuntipaiboontana R; Kruabkontho V; Ngernseng T; Tubprasert J; Abdad MY; Keayarsa S; Madmanee W; Aguiar RS; Santos FM; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Imwong M; Taylor WRJ; Chotivanich V; Chotivanich K; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
    BMC Infect Dis; 2024 Jan; 24(1):89. PubMed ID: 38225598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
    Zhao H; Zhang C; Zhu Q; Chen X; Chen G; Sun W; Xiao Z; Du W; Yao J; Li G; Ji Y; Li N; Jiang Y; Wang Y; Zeng Q; Li W; Gong B; Chang X; Zhu F; Jiang X; Li J; Wu Z; Liu Y; Peng P; Wang G
    Int Immunopharmacol; 2021 Aug; 97():107702. PubMed ID: 33930706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
    Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
    Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.
    Guner R; Hasanoglu I; Kayaaslan B; Aypak A; Akinci E; Bodur H; Eser F; Kaya Kalem A; Kucuksahin O; Ates I; Bastug A; Tezer Tekce Y; Bilgic Z; Gursoy FM; Akca HN; Izdes S; Erdem D; Asfuroglu E; Hezer H; Kilic H; Cıvak M; Aydogan S; Buzgan T
    J Infect Public Health; 2021 Mar; 14(3):365-370. PubMed ID: 33647553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial.
    Bosaeed M; Alharbi A; Mahmoud E; Alrehily S; Bahlaq M; Gaifer Z; Alturkistani H; Alhagan K; Alshahrani S; Tolbah A; Musattat A; Alanazi M; Jaha R; Sultana K; Alqahtani H; Al Aamer K; Jaser S; Alsaedy A; Ahmad A; Abalkhail M; AlJohani S; Al Jeraisy M; Almaziad S; Albaalharith N; Alabdulkareem K; Alshowair A; Alharbi NK; Alrabiah F; Alshamrani M; Aldibasi O; Alaskar A
    Clin Microbiol Infect; 2022 Apr; 28(4):602-608. PubMed ID: 35026375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.